Results 81 to 90 of about 2,262 (198)

Direct anti-HCV agents

Acta Pharmaceutica Sinica B, 2016
Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A ...
Xingquan Zhang
doaj   +1 more source

A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin

, 2016
Background and Aim: Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir plus asunaprevir in interferon (+/- ribavirin)-ineligible
Wei, Lai, Lu, Wei, McPhee, Fiona, Xu, Min, Li, Yueqi, Mo, Ling, Chen, Xinyue, Torbeyns, Anne, Yin, Philip D., Chuang, Wan-Long, Yang, Yong-Feng, Xie, Qing, Lin, Shumei, Zhang, Mingxiang, Xie, Wen, Bae, Si Hyun, Treitel, Michelle, Jia, Jidong, Gong, Guozhong, Jia, Zhansheng, Niu, Junqi, Garimella, Tushar   +21 more
core   +1 more source

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis

, 2018
Daclatasvir, asunaprevir, and beclabuvir are direct-acting antivirals for patients with hepatitis C virus genotype 1 infection. This systematic review and meta-analysis investigating the efficacy and safety of this three-drug combination in HCV genotype ...
Duy Hieu Truong (3338097)
core   +1 more source

Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report

BMC Nephrology, 2017
Background Direct-acting antivirals (DAAs) dramatically improve the treatment of hepatitis C virus (HCV) infections. However, the effects of DAAs on extra-hepatic manifestations such as HCV-associated glomerulonephritis, especially in cases with renal ...
Michiko Shimada, Norio Nakamura, Tetsu Endo, Hideaki Yamabe, Masayuki Nakamura, Reiichi Murakami, Ikuyo Narita, Hirofumi Tomita   +7 more
doaj   +1 more source

Modulation of chimeric antigen receptor surface expression by a small molecule switch

BMC Biotechnology, 2019
Background Engineered therapeutic cells have attracted a great deal of interest due to their potential applications in treating a wide range of diseases, including cancer and autoimmunity.
Alexandre Juillerat, Diane Tkach, Brian W. Busser, Sonal Temburni, Julien Valton, Aymeric Duclert, Laurent Poirot, Stéphane Depil, Philippe Duchateau   +8 more
doaj   +1 more source

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives

The Scientific World Journal, 2013
Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (
Hee Bok Chae, Seon Mee Park, Sei Jin Youn   +2 more
doaj   +1 more source

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

PLoS ONE, 2017
The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients. However, the risk in patients treated with interferon-free direct-acting antivirals (DAAs) is unknown. We
Yuko Nagaoki, Michio Imamura, Hiroshi Aikata, Kana Daijo, Yuji Teraoka, Fumi Honda, Yuki Nakamura, Masahiro Hatooka, Reona Morio, Kei Morio, Hiromi Kan, Hatsue Fujino, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Yoshiiku Kawakami, C Nelson Hayes, Daiki Miki, Hidenori Ochi, Kazuaki Chayama   +23 more
doaj   +1 more source

The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents

Kaohsiung Journal of Medical Sciences, 2017
Direct-acting antiviral agents (DAAs) have been widely used for chronic hepatitis C (CHC) treatment recently. The characteristics of glucose abnormalities after DAAs therapy however, remain elusive.
Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Meng-Hsuan Hsieh, Jeng-Fu Yang, Ching-I. Huang, Yi-Hung Lin, Po-Cheng Liang, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang   +12 more
doaj   +1 more source

Characterization of ADME properties of [¹⁴C]asunaprevir (BMS-650032) in humans

, 2016
1. Asunaprevir (ASV, BMS-650032), a highly selective and potent NS3 protease inhibitor, is currently under development for the treatment of chronic hepatic C virus infection. This study describes in vivo biotransformation in humans and the identification
Hao Jiang (95017), W. Griffith Humphreys (842751), Bing He (135034), Vinod Arora (842748), Ramaswamy A. Iyer (842752), Jiachang Gong (842746), Thomas Philip (842749), John Easter (842750), Timothy Eley (842747), Wenying Li (842753)   +9 more
core   +1 more source

Increase in albumin by daclatasvir/asunaprevir therapy is correlated with decrease in aspartate transaminase

, 2017
ObjectiveTo elucidate the mechanism of an increase in the albumin levels by daclatasvir (DCV)/asunaprevir (ASV) therapy, we assessed the factors associated with an increase in the albumin levels.MethodsWe retrospectively analyzed 125 patients with ...
Kentaro Yoshioka, Takuji Nakano, Toshiki Kan, Naoto Kawabe, Senju Hashimoto, Kazunori Nakaoka   +5 more
core   +1 more source